Physician profile
Robert A Munkelwitz
NPI 1578518627
$847.91
in general payments reported to CMS, 2019-2025
16 companies · $80.51 in 2025
The $80.51 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $15.19 · 2021: $93.57 · 2022: $106 · 2023: $167 · 2024: $73.40 · 2025: $80.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $190.84 | 2019-2022 | |
| Astellas Pharma US INC | $148.57 | 2019-2023 | Myrbetriq |
| Urogen Pharma, INC. | $129.44 | 2023 | Jelmyto |
| Ferring Pharmaceuticals INC. | $61.95 | 2024-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $56.94 | 2023-2025 | Gemtesa |
| Blue Earth Diagnostics | $43.59 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $32.92 | 2019-2022 | |
| Accord Healthcare, INC. | $30.83 | 2022 | |
| Dendreon Pharmaceuticals LLC | $26.70 | 2019 | |
| Myovant Sciences INC. | $23.33 | 2021 | |
| Boston Scientific Corporation | $21.07 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $17.27 | 2019 | |
| Endo USA, INC. | $16.84 | 2025 | Xiaflex |
| Daiichi Sankyo INC. | $16.54 | 2019 | |
| Tolmar, INC. | $15.71 | 2025 | Eligard |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sagent Pharmaceuticals | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Munkelwitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.